ENHANCING THE ROLE OF ARTIFICIAL INTELLIGENCE IN DIFFERENTIAL DIAGNOSIS OF MALIGNANT AND BENIGN BRAIN TUMORS USING MRI IMAGES

Authors

Abstract

Overlapping MRI features of malignant and benign brain tumors increase uncertainty in radiological interpretation, may lead to additional examinations, and can delay treatment decisions. The aim of this article is to substantiate a clinical and methodological algorithm for enhancing the diagnostic value of artificial intelligence in multiparametric MRI analysis. The proposed approach integrates T1, T2, FLAIR, DWI/ADC, SWI, perfusion imaging and post-contrast 3D T1 sequences with tumor segmentation, radiomic features, deep neural networks and explainable AI tools. The model includes image standardization, automated delineation of the tumor and peritumoral changes, classification of malignancy probability, and interpretable heat-map support for radiology reporting. Validation metrics, a clinical decision matrix and implementation criteria are proposed in accordance with STARD, CLAIM, TRIPOD+AI and AI-RANO principles. In conclusion, AI may strengthen radiological decision-making by quantifying subtle morphological, textural and volumetric signs relevant to differentiating malignant from benign brain tumors on MRI.

References

1.Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231-1251. doi:10.1093/neuonc/noab106.

2.Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro-Oncology. 2015;17(9):1188-1198. doi:10.1093/neuonc/nov095.

3.Wen PY, van den Bent M, Youssef G, Cloughesy T, Ellingson BM, Weller M, et al. RANO 2.0: update to the Response Assessment in Neuro-Oncology criteria for high- and low-grade gliomas in adults. Journal of Clinical Oncology. 2023;41(33):5187-5199. doi:10.1200/JCO.23.01059.

4.Menze BH, Jakab A, Bauer S, Kalpathy-Cramer J, Farahani K, Kirby J, et al. The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Transactions on Medical Imaging. 2015;34(10):1993-2024. doi:10.1109/TMI.2014.2377694.

5.Bakas S, Akbari H, Sotiras A, Bilello M, Rozycki M, Kirby JS, et al. Advancing The Cancer Genome Atlas glioma MRI collections with expert segmentation labels and radiomic features. Scientific Data. 2017;4:170117. doi:10.1038/sdata.2017.117.

6.Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nature Methods. 2021;18(2):203-211. doi:10.1038/s41592-020-01008-z.

7.Mongan J, Moy L, Kahn CE Jr. Checklist for Artificial Intelligence in Medical Imaging (CLAIM): A Guide for Authors and Reviewers. Radiology: Artificial Intelligence. 2020;2(2):e200029. doi:10.1148/ryai.2020200029.

8.Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378. doi:10.1136/bmj-2023-078378.

9.Villanueva-Meyer JE, Bakas S, Tiwari P, Lupo JM, Calabrese E, Davatzikos C, et al. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 1: review of current advancements. The Lancet Oncology. 2024;25(11):e581-e588. doi:10.1016/S1470-2045(24)00316-4.

10.Bakas S, Vollmuth P, Galldiks N, Booth TC, Aerts HJWL, Bi WL, et al. Artificial Intelligence for Response Assessment in Neuro Oncology (AI-RANO), part 2: recommendations for standardisation, validation, and good clinical practice. The Lancet Oncology. 2024;25(11):e589-e601. doi:10.1016/S1470-2045(24)00315-2.

11.Litjens G, Kooi T, Bejnordi BE, Setio AAA, Ciompi F, Ghafoorian M, et al. A survey on deep learning in medical image analysis. Medical Image Analysis. 2017;42:60-88. doi:10.1016/j.media.2017.07.005.

12.Sanvito F, Castellano A, Falini A, et al. Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration. Frontiers in Radiology. 2023;3:1267615. doi:10.3389/fradi.2023.1267615.

13.Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJWL. Artificial intelligence in radiology. Nature Reviews Cancer. 2018;18(8):500-510. doi:10.1038/s41568-018-0016-5.

14.Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology. 2017;14(12):749-762. doi:10.1038/nrclinonc.2017.141.

15.Kickingereder P, Neuberger U, Bonekamp D, Piechotta PL, Götz M, Wick A, et al. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology. 2016;280(3):880-889. doi:10.1148/radiol.2016160845.

16.Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ. 2015;351:h5527. doi:10.1136/bmj.h5527.

Published

2026-09-25